Huadong Medicine Co., Ltd (SHE:000963)
China · Delayed Price · Currency is CNY | Market Cap | 62.88B +5.0% |
| Revenue (ttm) | 43.09B +3.3% |
| Net Income | 3.70B +15.1% |
| EPS | 2.11 +14.8% |
| Shares Out | 1.75B |
| PE Ratio | 17.07 |
| Forward PE | 17.24 |
| Dividend | 0.93 (2.56%) |
| Ex-Dividend Date | n/a |
| Volume | 7,023,386 |
| Average Volume | 10,724,225 |
| Open | 36.38 |
| Previous Close | 35.94 |
| Day's Range | 35.70 - 36.62 |
| 52-Week Range | 33.10 - 47.36 |
| Beta | 0.34 |
| RSI | 52.67 |
| Earnings Date | Apr 24, 2026 |
About Huadong Medicine
Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. It operates through Pharmaceutical Industry, Pharmaceutical Business, Aesthetic Medicine, and Industrial Microbiology segments. The company distributes Chinese and western medicines, Chinese herbal medicines, and medical instruments; and immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, antibiotic drugs, medical beauty field products, ... [Read more]
Financial Performance
In 2024, Huadong Medicine's revenue was 41.91 billion, an increase of 3.16% compared to the previous year's 40.62 billion. Earnings were 3.51 billion, an increase of 23.72%.
Financial StatementsNews
CARsgen Therapeutics Announces 2025 Annual Results
SHANGHAI , March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Res...